IL6 and Miyoshi myopathy: Consistently with the notion that the dynamic milieu generated by the cytokines/chemokines as a whole may dictate treatment response and disease outcome, recent studies have revealed that combinatorial therapies with PIs plus anticytokine/chemokine (eg anti‐IL6) treatment could have beneficial effect on MM therapy and on MM‐related bone disease.60